J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1 Suppl. 2):61-64. doi: 10.23812/21-1supp2-12.



>>> Request Full Article

Magnesium alginate in patients with laryngopharyngeal reflux

Ciprandi G1, Damiani V2, Passali FM3, Crisanti A4, Motta G5, Passali D6.

Author information

1 Consultant allergist, Casa di Cura Villa Montallegro, Genoa, Italy.
2 Medical Department, D.M.G. Italia, Pomezia, Italy.
3 Department of Clinical Sciences and Translational Medicine, University of Tor Vergata, Rome, Italy.
4 Clinical Medicine Department, Regina Apostolorum Hospital, Albano Laziale, Rome, Italy.
5 ENT Clinic, University Vanvitelli, Naples, Italy.
6 International Federation ORL Societies (IFOS) Executive Board members Rome Italy.

Abstract

Laryngopharyngeal reflux (LPR) is a common disease caused by the leaking beck of gastric material out of the esophagus. The main symptoms are dysphonia, dysphagia, and cough. There is an established use of proton pump inhibitors (PPI) in patients with suspected LPR in common practice. This habit is translated by the standard strategy to use PPI in treating patients with gastroesophageal reflux. However, PPI can not wholly inhibit all types of reflux and are burden by adverse effects. Alginate, a derivative from algae, is devoid of side effects and effectively counteracts gastric material reflux forming a foaming gel in the stomach. The current study enrolled 100 outpatients with LPR. Alginate treatment was administered for two months. Patients underwent four visits (at baseline and 15, 30, and 60 days after treatment). A visual analog scale assessed the perception of dysphonia, dysphagia, and cough. Alginate significantly (p<0.0001) reduced all parameters. Therefore, the current study demonstrated that magnesium alginate was effective and safe in LPR treatment.

KEYWORDS:

cough, dysphagia, dysphonia, laryngopharyngeal reflux, magnesium alginate

Publication type

  • Observational Study

>>> Request Full Article

You may also like...